The Epstein-Barr virus and its association with human cancers

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 6, 1999, Pages 307-322

  Baumforth, K R N ^a   Young, L S ^b   Flavell, K J ^a   Constandinou, C ^a   Murray, P G ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Burkitt's lymphoma; Epstein Barr virus; Hodgkin's disease; Nasopharyngeal carcinoma; Post transplant lymphoproliferative disease; T cell lymphoma

Indexed keywords

BURKITT LYMPHOMA; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA;

EID: 0013006220     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.6.307     Document Type: Review

References (187)

1. Given D, Yee D, Griem K, et al. DNA of Epstein-Barr virus: V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol 1979;30:852-62.
2. Cheung A, Kieff E. Long internal direct repeat in Epstein-Barr virus DNAs. J Virol 1982;44:286-94.
3. Sixbey JW, Nedrud JG, Raab-Traub N, et al. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984;310:1225-30.
4. Gerber P, Goldstein L, Lucas S, et al. Oral excretion of Epstein-Barr viruses by healthy subjects and patients with infectious mononucleosis. Lancet 1972;2:988-9.
5. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968;59:94-101.
6. Rickinson A, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincot-Raven, 1996:2397-446.
7. Tosato G, Blaese RM. Epstein-Barr virus infection and immunoregulation in man. Adv Immunol 1985;37:99-149.
8. Israele V, Shirley P, Sixbey JW. Excretion of the Epstein-Barr-virus from the genital tract of men. J Infect Dis 1991; 163:1341-3.
9. Junker AK, Thomas EE, Radcliffe A, et al. Epstein-Barr virus shedding in breast milk. Am J Med Sci 1991;302:220-3.
10. Sixbey JW, Lemon SM, Pagano JS. A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet 1986;2:1122-4.
11. Ernberg I, Andersson J. Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis. J Gen Virol 1986;67:2267-72.
12. Yao Q, Ogan P, Rowe M, et al. Epstein-Barr virus infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989;43:67-71.
13. Gratama JW, Oosterveer MA, Lepoutre JM, et al. Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients [published erratum appears in Transplantation 1990;50:910]. Transplantation 1990;49:725-30.
14. Alfieri C, Birkenbach M, Kieff E. Early events in Epstein-Barr virus infection of human B-lymphocytes. Virology 1991;181:595-608.
15. Mosier DE, Gulizia RJ, Baird SM, et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988;335:256-9.
16. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-93.
17. Oudejans JJ, van den Brule AJ, Jiwa NM, et al. BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood 1995;86:1893-902.
18. Jiwa NM, Oudejans JJ, Bai MC, et al. Expression of bcl-2 protein and transcription of the Epstein-Barr virus bcl-2 homologue BHRF-1 in Hodgkin's disease: implications for different pathogenic mechanisms. Histopathology 1995;26:547-53.
19. Henderson A, Ripley S, Heller M, et al. Human chromosome association of Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth transformed in vitro. Proc Natl Acad Sci USA 1983;80:1987-91.
20. Young LS, Yao QY, Rooney CM, et al. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol 1987;68:2853-62.
21. Sixbey JW, Shirley P, Chesney PJ, et al. Detection of a second widespread strain of Epstein-Barr virus. Lancet 1989;2:761-5.
22. Borisch B, Finke J, Hennig I, et al. Distribution and localization of Epstein-Barr virus subtypes A and B in AIDS-related lymphomas and lymphatic tissue of HIV-positive patients. J Pathol 1992;168:229-36.
23. Lung ML, Chang GC, Miller TR, et al. Genotypic analysis of Epstein-Barr virus isolates associated with nasopharyngeal carcinoma in Chinese immigrants to the United States. Int J Cancer 1994;59:743-6.
24. Bouzid M, Djennaoui D, Dubreuil J, et al. Epstein-Barr virus genomes in NPC biopsies from North Africa. Int J Cancer 1994;56:468-73.
25. Lung ML, Lam WP, Chan KH, et al. Direct detection of Epstein-Barr virus in peripheral blood and comparison of EBV genotype present in direct specimens and lymphoblastoid cell lines established from nasopharyngeal carcinoma patients and healthy carriers in Hong Kong. Int J Cancer 1992;52:174-7.
26. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996;15:3117-26.
27. Magrath I, Jain V, Bhatia K. Molecular epidemiology of Burkitt's lymphoma. The Epstein-Barr Virus and Associated Diseases 1993;225:377.
28. Abbot SD, Rowe M, Cadwallader K, et al. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol 1990;64:2126-34.
29. Wang F, Gregory CD, Rowe M, et al. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci USA 1987;83:3452-7.
30. Wang F, Tsang S, Kurila M, et al. Epstein-Barr virus nuclear antigen 2 transactivates the latent membrane protein (LMP1). J Virol 1990;64:3407-16.
31. Zimber-Strobl U, Suentzenich KO, Laux G, et al. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol 1991;65:415-23.
32. Tomkinson B, Kieff E. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in-vitro. J Virol 1992;66:2893-903.
33. Tomkinson B, Robertson E, Kieff, E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 1993;67:2014-25.
34. Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein 1 (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B-lymphocytes: EBNA2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-18.
35. Le Roux A, Kerdiles B, Walls D, et al. The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2 mediated transactivation of the viral terminal protein 1 gene promoter. Virology 1994;205:596-602.
36. Sample J, Henson EB, Sample C. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J Virol 1992;66:4654-61.
37. Mannick JB, Cohen JI, Birkenbach M, et al. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 1991;65:6826-37.
38. Sinclair AJ, Palermo I, Peters G, et al. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 1994;13:3321-8.
39. Cheng G, Baltimore D. TANK, a co-inducer with TRAF2 of TNF-and CD40L-mediated NF-κB activation. Genes Dev 1996;10:963-73.
40. Szekely L, Selivanova G, Magnusson KP, et al. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 1993;90:5455-9.
41. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;34:831-40.
42. Baichwal VR, Sugden B. Transformation of Balb/3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 1988; 2:461-7.
43. Gregory CD, Dive C, Henderson S, et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991;349:612-14.
44. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein protects infected B cells from programmed cell death. Cell 1991;65:1071-115.
45. Laherty CD, Hu MM, Opipari AW, et al. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 1992;267:24157-60.
46. Eliopoulos AG, Stack M, Dawson CW, et al. Epstein-Barr virus encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF-receptor-associated factors. Oncogene 1997;14:2899-16.
47. Nakagomi H, Dolcetti R, Bejarano MT, et al. The Epstein-Barr-virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt-lymphoma lines. Int J Cancer 1994;57:240-4.
48. Withdrawn.
49. Wilson JB, Weinberg W, Johnson R, et al. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990;61:1315-27.
50. Fahraeus R, Rymo L, Rhim JS, et al. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990;345:447-9.
51. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-80.
52. Huen DS, Henderson SH, Croom-Carter D, et al. The Epstein-Barr virus latent membrane protein (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxyl-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
53. Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus encoded latent membrane protein-1. Oncogene 1998; 16:1731-42.
54. Eliopoulos AG, Gallagher NJ, Blake SMS, et al. Activation of the p38 mitogen activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999;274:16085-96.
55. Gires O, Kohlhuber F, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 1999;18:3064-73.
56. Izumi KM, Kieff ED. The Epstein-Barr virus oncogenic product latent membrane protein 1 engages the tumour necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci USA 1997;94:12592-7.
57. Kaye KM, Izumi KM, Mosialos G, et al. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation: fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 1995;69:675-83.
58. Knecht H, Bachmann E, Brousset P, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993;82:2937-42.
59. Li SN, Chang YS, Liu ST. Effect of a 10 amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 1996;12:2129-35.
60. Devergne O, Hatzivassiliou E, Izumi KM, et al. TRAF1, TRAF2, and TRAF3 effect NF-κB activation by an Epstein-Barr virus LMP1 domain important for B lymphocyte transformation. Mol Cell Biol 1996;16:7098-108.
61. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumour necrosis factor receptor family. Cell 1995;80:389-99.
62. Sandberg M, Hammerschmidt W, Sugden B. Characterisation of LMP1s association with TRAF1, TRAF2, and TRAF3. J Virol 1997;71:4649-56.
63. Eliopoulos AG, Blake SMS, Floettmann JE, et al. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through it's extreme C-terminus via a mechanism involving TRADD and TRAF2. J Virol 1999;73:1023-35.
64. Leonard WJ, O'Shea JJ. JAKS and STATS: biological implications. Annu Rev Immunol 1998;16:293-322.
65. Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997;16:6131-40.
66. Floettmann JE, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene 1997;15:1851-8.
67. Hatzivassilou E, Miller WE, Raab-Traub N, et al. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor κB, and stress activated protein kinase. J Immunol 1998;3:1116-21.
68. Longnecker R, Kieff E. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and co-localises with LMP1. J Virol 1990;64:2319-26.
69. Fruehling S, Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR mediated signal transduction. Virology 1997;235:241-51.
70. Miller CL, Burkhardt AL, Lee JH, et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 1995;2:155-66.
71. Miller CL, Lee JH, Kieff E, et al. Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sLg-mediated signal transduction. Infect Agents Dis 1994;3:128-36.
72. Brielmeier M, Mautner J, Laux G, et al. The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J Gen Virol 1996;77:2807-18
73. Swaminathan S, Tomkinson B, Kieff E. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in-vitro. Proc Natl Acad Sci USA 1991;88:1546-50.
74. Clarke PA, Schwemmie M, Schickinger J, et al. Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic Acids Res 1991;19:243-8.
75. Clemens MJ. Functional significance of the Epstein-Barr virus-encoded small RNAs. EBV Report 1994;5:107-11.
76. Lerner MR, Andrews NC, Miller G, et al. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with lupus erythematosus. Proc Natl Acad Sci USA 1981;78:805-9.
77. Toczyski DP, Matera AG, Ward DC, et al. The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalises ribosomal protein L22 in EBV infected human B-lymphocytes. Proc Natl Acad Sci USA 1994;91:3463-7.
78. Bhat RA, Thimmappaya B. Two small RNAs encoded by Epstein-Barr virus can functionally substitute for the virus-associated RNAs in the lyric growth of adenovirus 5. Proc Natl Acad Sci USA 1983;80:4789-93.
79. Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987;129:86-91.
80. Staal SP, Ambinder R, Beschorner WE, et al. A survey of Epstein-Barr virus DNA in lymphoid tissue: frequent detection in Hodgkin's disease. Am J Clin Pathol 1989;91:1-5.
81. Herbst H, Niedobitek G, Kneba M, et al. High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol 1990;137:13-18.
82. Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 1990;46:801-4.
83. Barletta JM, Kingma DW, Charache P, et al. Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection. Mol Cell Probes 1993:7;105-9.
84. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320-2.
85. Murray PG, Young LS, Rowe M, et al. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol 1992;166:1-5.
86. Brink AA, Dukers DF, van den Brule AJ, et al. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol 1997;50:911-18.
87. Grasser F, Murray PG, Kremmer E, et al. Monoclonal antibodies directed against the Epstein-Barr virus encoded nuclear antigen 1: immmunohistological detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 1994;84:3792-8.
88. Murray PG, Niedobitek G, Kremmer E, et al. In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol 1996;178:44-7.
89. Niedobitek G, Kremmer E, Herbst H, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 1997;90:1664-72.
90. Murray PG, Constandinou CM, Crocker J, et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Immunity to EBV in healthy virus carriers. Blood 1998;92:2477-83.
91. Henle W, Henle G, Zajac BA, et al. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 1970;169:188-90.
92. Moss DJ, Burrows SR, Khanna R, et al. Immune surveillance against Epstein-Barr virus. Semin Immunol 1992;4:97-104.
93. Sheldon PJ, Papamichail M, Hemsted EH, et al. Thymic origin of atypical lymphoid cells in IM. Lancet 1973;I:1153-5.
94. Moss DJ, Rickinson AB, Pope JH. Long-term T cell mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 1978;22:662-8.
95. Moss DJ, Rickinson AB, Pope JH. Long-term T cell mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leucocyte cultures. Int J Cancer 1979;23:618-25.
96. Misko IS, Sculley TB, Schmidt C, et al. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4′ cytotoxic T cell clones and includes an Epstein-Barr virus-specific component. Cell Immunol 1991;132:295-307.
97. Gavioli R, Kurilla M, de Campos-Lima PO, et al. Multiple HLA A11 restricted CTL epitopes of different immunogenicities in the Epstein-Barr virus encoded nuclear antigen-4 (EBNA4). J Virol 1993;67:1572-8.
98. Levitsky V, Zhang QJ, Levitskaya J, et al. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T-lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 1996; 183:915-26.
99. + population. Science 1993;260:98-100.
100. de Campos-Lima PO, Levitsky V, Brooks J, et al. T cell responses and virus evolution: Epstein-Barr virus isolates from highly HLA A11-positive populations carry mutations selectively involving anchor residues of A11-restricted CTL epitopes. J Exp Med 1994;179:1297-305.
101. Trivedi P, Masucci MG, Winberg G, et al. The Epstein-Barr virus encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. Int J Cancer 1991;48:794-800.
102. Khanna R, Burrows SR, Steigerwald-Mullen PM, et al. Isolation of cytotoxic T-lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 1995;214:633-7.
103. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-8.
104. Lee SP, Thomas WA, Murray RJ, et al. HLA A2.1 restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993;67:7428-35.
105. Sing A, Ambinder RF, Hong DJ, et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy for Hodgkin's disease. Blood 1997;89:1978.
106. Nalesnik MA, Jaffe R, Starzl, et al. The pathology of post transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-92.
107. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72:520-9.
108. Withersponn RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989;321:784-9.
109. Crawford DH, Thomas JA, Janossy G, et al. Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patients with renal allograft. Lancet 1980;I:1355-6.
110. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
111. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusion of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;331:679-80.
112. Heslop HE, Ng CYC, Smith CA, et al. Long term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5.
113. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-5.
114. Cen H, Williams PA, McWilliams HP, et al. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993;81:1393-403.
115. Murray PG, Swinnen LJ, Constandinou CM, et al. bcl-2 but not the EBV-encoded bcl-2 homologue, BHRF1, is commonly expressed in post-transplantation lymphoproliferative disorders. Blood 1996;87:706-11.
116. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-65.
117. Polack A, Hortnagel K, Pajic A, et al. MYC activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci USA 1996;93:10411-16.
118. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998;92:2294-302.
119. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998;338:1413-21.
120. Rickinson AB. Epstein-Barr virus in action in vivo. N Engl J Med 1998;338:1461-3.
121. Cen H, Breinig MC, Atchison RW, et al. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4. J Virol 1991;65:976-80.
122. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985;152:876-86.
123. MacMahon EME, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969-73.
124. Boyle MT, Sewell WA, Sculley TB, et al. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood 1991;78:3004-11.
125. Cesarman E, Chang YI, Moore PS, et al. Kaposi's sarcoma associated herpesvirus-like DNA sequences in AIDS-related body cavity based lymphomas. N Engl J Med 1995; 332:1186-91.
126. Shibata M, Weiss LM, Nathwani BN, et al. Epstein-Barr virus in benign lymph-node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma. Blood 1991;77:1527-33.
127. Carbone A, Tirelli U, Gloghini A, et al. Human immunodeficiency-virus-associated systemic lymphomas may be subdivided into two main types according to Epstein-Barr virus gene expression. J Clin Oncol 1993;11:1674-81.
128. Razzouk BI, Srinivas S, Sample CE, et al. Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 1996;173:529-35.
129. Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991;77:1516-26.
130. Lam KMC, Syed N, Whittle H, et al. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet 1991;337:876-8.
131. Gregory CD, Rowe DM, Rickinson AB. Different Epstein-Barr virus (EBV) B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J Gen Virol 1990;71:1481-95.
132. Hatzubai A, Anafi M, Masucci MG, et al. Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer 1987;40:358-64.
133. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743-51.
134. Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogenous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995;86:659-65.
135. Carbone A, Gloghini A. Expression of Epstein-Barr virus encoded latent membrane protein-1 in non-endemic Burkitt's lymphoma. Blood 1995;87:1202-4.
136. McMichael A, Bodmer WF, eds. A new look at tumour immunology. New York: CSHL Press, 1992.
137. de Campos-Lima PO, Torsteinsdottir S, Cuomo L, et al. Antigen processing and presentation by EBV-carrying cell lines: cell-phenotype dependence and influence of the EBV-encoded LMP1. Int J Cancer 1993;53:856-62.
138. Khanna R, Burrows SR, Agaet V, et al. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restore immunogenicity of an antigen processing defective tumor cell line. Int Immunol 1994;6:639-45.
139. Lombardi L, Newcomb E, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene in lymphoblasts. Cell 1987;49:161-70.
140. Polack A, Hortnagel K, Pajic A, et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci USA 1996;93:10411-16.
141. Qu L, Rowe DT. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 1992; 66:3715-24.
142. Tierney RJ, Steven N, Young LS, et al. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994;69:7374-85.
143. Shimizu N, Tanabe-Tochikiura A, Kuroiwa Y, et al. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 1994;68:6069-73.
144. Gutensohn N, Cole P. Epidemiology of Hodgkin's disease. Semin Oncol 1980;7:92-102.
145. Levine PH, Ablashi DV, Berard CW, et al. Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer 1971;27:416-21.
146. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989;32:689-95.
147. Alexander FE, Daniel CP, Armstrong AA, et al. Case clustering, Epstein-Barr virus Reed-Sternberg cell status and herpes virus serology in Hodgkin's disease: results of a case control study. Eur J Cancer 1995;31A:1479-86.
148. Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987;129:86-91.
149. Chang KL, Albujar PF, Chen Y-Y, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993;81:496-501.
150. Weinreb M, Day PJR, Niggli F, et al. The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 1996;87:3828-36.
151. Anagnostopoulos I, Herbst H, Niedobitek G, et al. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989;74:810-16.
152. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993;177:339-49.
153. Jarrett RF, Gallagher A, Jones DB, et al. Detection of EBV genomes in Hodgkin's disease: relation to age. J Clin Pathol 1991;44:844-8.
154. Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia 1998;12:1272-6.
155. Uccini S, Monardo F, Stoppacciaro A, et al. High frequency of Epstein-Barr virus genome detection in Hodgkin's disease of HIV-positive patients. Int J Cancer 1990;46:581-5.
156. Flavell K, Constandinou C, Lowe D, et al. Effect of material deprivation on Epstein-Barr virus infection in Hodgkin's disease in the West Midlands. Br J Cancer 1999;80:604-8.
157. d'Amore F, Iohansen P, Houmand A, et al. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in non-lymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 1996;87:1045-55.
158. Borisch B, Hennig I, Laeng RH, et al. Association of the subtype 2 of the Epstein-Barr virus with T-cell non-Hodgkin lymphoma of the midline granuloma type. Blood 1993;82:858-64.
159. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47:883-9.
160. Klein G. The relationship of the virus to nasopharyngeal carcinoma. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin: Springer-Verlag, 1979:339-50.
161. Weiss LM, Movahed LA, Butler AE, et al. Analysis of lymphoepithelioma and lymphoepithelioma-like carcinomas for Epstein-Barr virus by in situ hybridization. Am J Surg Pathol 1989;13:625-31.
162. Niedobitek G, Hansmann ML, Herbst H, et al. Epstein-Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol 1991;165:17-24.
163. Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988;69:1051-65.
164. Niedobitek G, Young LS, Sam CK, et al. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol 1992;140:879-87.
165. Brooks L, Yao QY, Rickinson AB, et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992;66:2689-97.
166. Gilligan K, Rajadurai P, Lin J-C, et al. Expression of the Epstein-Barr virus Bam HI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol 1991;65:6252-9.
167. Brooks L, Lear AL, Young LS, et al. Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 1993;67:3182-90.
168. Cochet C, Martel-Renoir D, Grunewald V, et al. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 1993;197:358-65.
169. Zheng X, Yan I, Nilsson B, et al. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncolog 1994;33:867-72.
170. Mazeron MC. Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx. Bull Cancer Radiother 1996; 83:3-7.
171. Raab-Traub N, Flynn K, Pearson G, et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer 1987;39:25-9.
172. Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, non-keratinising, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995;146:1355-67.
173. Yeung WM, Zong YS, Chiu CT, et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 1993;53:746-50.
174. Raab-Traub N, Gilligan K, Sato H, et al. EBV DNA structure and expression in EBV-induced proliferations. In: Ablashi DV, Faggioni A, Krueger GRF, et al, eds. Epstein-Barr virus and human disease. Clifton, NJ: Humana Press, 1988:85-98.
175. Sam CK, Brooks LA, Niedobitek G, et al. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a high nasopharyngeal carcinoma risk group. Int J Cancer 1993;53:957-62.
176. Ho JHC. Current knowledge of the epidemiology of nasopharyngeal carcinoma. In: Biggs P, de The G, Payne L, eds. Oncogenesis and herpesviruses. Lyon: IARC, 1972:357-66.
177. Fujii T, Kawai T, Saito K, et al. EBER-1 expression in thymic carcinoma. Acta Pathol Jpn 1993;43:107-10.
178. Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91:9131-5.
179. Weinberg E, Hoisington S, Eastman AY, et al. Uterine cervical lymphoepithelial-like carcinoma. Absence of Epstein-Barr virus. Am J Clin Pathol 1993;99:195-9.
180. Shanmugaratnam K, Sobin LH. Histological typing of upper respiratory tract tumours. Geneva: WHO, 1978.
181. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769-74.
182. Gulley ML, Pulitzer DR, Eagan PA, et al. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996;27:20-7.
183. Raab-Traub N, Rajadurai P, Flynn K, et al. Epstein-Barr virus infection in carcinoma of the salivary gland. J Virol 1991;65:7032-6.
184. Selves J, Bibeau F, Brousset P, et al. Epstein-Barr virus latent and replicative gene expression in gastric carcinoma. Histopathology 1996;28:121-7.
185. Niedobitek G, Herbst H, Young LS, et al. Epstein-Barr virus and carcinomas: expression of the viral genome in an undifferentiated gastric carcinoma. Diagn Mol Pathol 1992; 1:103-8.
186. Bonnet M, Guinebretiere JM, Kremmer E, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1990;91:1376-81.
187. Sugawara Y, Mizugaki Y, Uchida T, et al. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology 1999;256:196-202.